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Abstract
Background: The first FDA-approved test to assess risk for acute kidney injury (AKI), [TIMP-2]•[IGFBP7], is clinically
available in many parts of the world, including the USA and Europe. We sought to understand how the test is
currently being used clinically.
Methods: We invited a group of experts knowledgeable on the utility of this test for kidney injury to a panel
discussion regarding the appropriate use of the test. Specifically, we wanted to identify which patients would be
appropriate for testing, how the results are interpreted, and what actions would be taken based on the results of
the test. We used a modified Delphi method to prioritize specific populations for testing and actions based on
biomarker test results. No attempt was made to evaluate the evidence in support of various actions however.
Results: Our results indicate that clinical experts have developed similar practice patterns for use of the [TIMP-
2]•[IGFBP7] test in Europe and North America. Patients undergoing major surgery (both cardiac and non-cardiac),
those who were hemodynamically unstable, or those with sepsis appear to be priority patient populations for
testing kidney stress. It was agreed that, in patients who tested positive, management of potentially nephrotoxic
drugs and fluids would be a priority. Patients who tested negative may be candidates for “fast-track” protocols.
Conclusion: In the experience of our expert panel, biomarker testing has been a priority after major surgery,
hemodynamic instability, or sepsis. Our panel members reported that a positive test prompts management of
nephrotoxic drugs as well as fluids, while patients with negative results are considered to be excellent candidates
for “fast-track” protocols.
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Introduction
Apart from renal replacement therapy, no direct treatment
exists for acute kidney injury (AKI). Many researchers have
argued that therapies could be translated from promising
preclinical results if—and likely only if—patients could be
identified in the very early stages of injury. Likewise, clini-
cians argue that early treatment—before irreversible injury
occurs—would be much more likely to succeed than would
potential interventions to reverse established AKI. The
2012 Kidney Disease: Improving Global Outcomes
(KDIGO) clinical practice guideline [1] for AKI lists 12
actions; 6 measures should be implemented in patients at
high risk for AKI, and only 6 are intended for patients with
established AKI, whereas none are curative (Fig. 1).
To this end, researchers around the world have discov-
ered biomarkers that can be detected in the blood or
urine of patients before AKI is evident using standard
clinical criteria (e.g., changes in serum creatinine and
urine output). N-Acetyl-β-D-glucosaminidase (NAG),
neutrophil gelatinase-associated lipocalin (NGAL), kid-
ney injury molecule-1 (KIM-1), interleukin-18 (IL-18),
and liver fatty acid-binding protein (L-FABP) were
among the first candidates [1, 2]. More recently, tissue
inhibitor of metalloproteinases-2 (TIMP-2) and insulin-
like growth factor binding protein 7 (IGFBP7) have been
added to the list [2]. With varying degrees of accuracy,
these markers all provide information about the state of
the kidney much earlier than do changes in function
(i.e., serum creatinine).
In response to clinical need and their assessment of cur-
rently available evidence, some institutions have become
early adopters of AKI biomarker technology. Because only
one biomarker test is currently FDA approved for use in
the USA, we focused on the NephroCheck® test (Astute
Medical), which combines TIMP-2 and IGFBP7 ([TIMP-
2]•[IGFBP7]). This test is also CE-marked (Conformité
Européenne) and available in several European countries
including France, Germany, Italy, Austria, Switzerland, the
UK, and Spain. We sought to understand the following
features of use to help determine how the test is currently
being used: (1) Who are the target patients for [TIMP-
2]•[IGFBP7] testing? (2) When are patients being tested
(and retested)? (3) How are quantitative [TIMP-
2]•[IGFBP7] test results being interpreted? (4) What actions
are taken based on test results? To address these issues, a
working group of clinical experts convened meetings to
discuss their collective experience about the practicalities of
implementing this test and to obtain group consensus
regarding the most important clinical management actions
to consider after obtaining a positive or negative test result.
We recognize that many clinical actions are unproven, and
we make no clinical recommendation on their use. Instead,
our intent was to understand how the biomarker test was
being used at sites that have adopted it.
Methods
Invitations were sent to experts in critical care, nephrol-
ogy, and surgery who had significant clinical experience
Fig. 1 Stage-based management of acute kidney injury. Shading of boxes indicates priority of action; solid shading indicates actions that are
equally appropriate at all stages whereas graded shading indicates increasing priority as intensity increases. AKI: acute kidney injury; ICU: intensive
care unit. Source: Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical Practice Guideline for
Acute Kidney Injury. Kidney Inter Suppl 2012, 2(1):1–138
Guzzi et al. Critical Care          (2019) 23:225 Page 2 of 9
with the biomarker. All invited experts were expected to
have substantial experience using the test in clinical
practice (i.e., not just in research studies). The recruit-
ment of experts was based on personal knowledge of the
investigators. Invitations were sent to 19 experts; 16
accepted. In 2018, two meetings were held, one in the
USA and another in Europe, where experts described
and discussed their clinical experiences with the use of
[TIMP-2]•[IGFBP7] at their various institutions.
In advance of the meetings, invitees completed a ques-
tionnaire (Additional file 1: Table S1). The questionnaire
was designed to collect information about different
aspects of [TIMP-2]•[IGFBP7] testing, including factors
that led to adoption at respondents’ respective institutions,
specific items related to testing procedures, and interpret-
ation of results. Collated results of the questionnaire were
provided to group members before the meetings, so they
could become familiar with all of the responses and be
prepared to discuss the findings at each meeting.
In addition, participants were encouraged to provide
their individual institution protocols and/or written
instructions they had developed or with which they
were familiar. These protocols were analyzed for com-
mon elements, and then rank-ordered by all partici-
pants (Table 1). The rank order of positive and negative
[TIMP-2]•[IGFBP7] protocol actions and avoidances,
respectively, may have had redundant bins, potentially
skewing the “count” results. However, the goal of the
protocol evaluation was to determine the best consen-
sus actions using as many examples as possible rather
than obtaining the most accurate “count” of protocol
actions.
At each meeting, the available protocols and question-
naire results were reviewed, and the panel agreed to discuss
the four key questions related to the goals of the meeting:
i. Who are the target patients for [TIMP-2]•[IGFBP7]
testing?
ii. When are patients being tested (and retested)?
iii. How are quantitative [TIMP-2]•[IGFBP7] test
results being interpreted?
iv. What actions are taken based on test results?
Each question was then answered based on the clinical
experience of the group along with information from the
medical literature when available.
Next, we conducted a two-step modified Delphi
process to ensure that our results were complete (step 1)
and prioritized by the group (step 2). This process
involved a single round of voting for each step. Ballots
were anonymous to all but the senior author who tabu-
lated the results. Figure 2 is a schematic representation
of the steps involved before, during, and after the expert
panel meetings.
Results
Q1. Who are the target patients for [TIMP-2]•[IGFBP7]
testing?
The expert panel agreed on key candidates for biomarker
testing based on their direct experience, with the caveat
that this list might not be exhaustive. Proposed target pop-
ulations are specified in rank order in Table 2. Postopera-
tive cardiac or major vascular surgery was the most
strongly supported followed by shock/hemodynamically
unstable patients regardless of the cause and sepsis (with
or without shock). Further down on the list, but still with
strong support, were postoperative non-cardiovascular
major surgery, cardiac arrest/extracorporeal membrane
oxygenation, and patients with persistent oliguria after re-
suscitation. Additional populations suggested by the group
are shown in Table 2.
Q2. When are patients being tested (and retested)?
In general, [TIMP-2]•[IGFBP7] testing has been ordered
for patients when the kidney is under threat for any rea-
son—when something creates a toxic event in the kidney,
when there is a question of secondary nephrotoxicity, or at
any time a significant change in status has occurred that
might result in kidney injury. Most users found that
[TIMP-2]•[IGFBP7] testing is particularly useful within the
first 72 h of ICU admission. Therefore, [TIMP-2]•[IGFBP7]
testing is most often being ordered in patients at risk for
AKI, including those who are hemodynamically unstable,
in respiratory failure, or exhibiting Stage 1 AKI (Fig. 3).
Specific clinical scenarios (e.g., cardiac surgery, sepsis) were
identified where appropriate testing might differ.
Q3. How are quantitative [TIMP-2]•[IGFBP7] test results
being interpreted?
The FDA has approved the cutoff threshold of > 0.3,
which ensures that > 92% of all stages 2/3 AKI events
over the following 12 h are predicted [3–5]. A low risk
for AKI is defined as a test result ≤ 0.3. Moderate risk is
defined as having a result of > 0.3 and ≤ 2.0; high risk is
associated with a result > 2.0. Thus, as test results
increase, so does the level of kidney stress and the risk
of AKI. If the result is > 0.3, there is a “risk” and any po-
tential damage needs to be averted [6, 7]. All of the pro-
tocols reviewed used the 0.3 cutoff to separate low from
moderate-high risk. A few protocols also specified ac-
tions related to the 2.0 cutoff, which generally related to
increasing intensity of actions triggered by the 0.3 cutoff
(e.g., more frequent monitoring of serum creatinine).
Q4. What actions are taken based on test results?
Meeting participants discussed and came to consensus re-
garding recommended actions (both positive and nega-
tive—i.e., things to do as well as things not to do) when
the [TIMP-2]•[IGFBP7] test is positive. A complete list of
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rank-ordered actions after a positive or negative [TIMP-
2]•[IGFBP7] test is provided in Table 3. Actions chosen by
the group were often found in the KDIGO guideline, as well
as in more recent recommendations for prevention of AKI
[1, 8]. The highest priority actions fell into two domains,
management of nephrotoxins and fluids. Top priority was
given to “discontinue all nonessential potential nephrotoxins
(e.g., NSAIDs [nonsteroidal anti-inflammatory drugs])”;
avoiding vancomycin (or dose adjusting) especially combina-
tions of vancomycin with aminoglycosides or piperacillin
tazobactam, and discontinuing angiotensin-converting
enzyme (ACE) inhibitors or angiotensin-receptor blockers
(ARBs) were ranked second and fourth. Goal-directed fluid
management (e.g., bedside ultrasound and functional
hemodynamic monitoring) was ranked third, and
retaining invasive hemodynamic monitoring was ranked
seventh. A negative [TIMP-2]•[IGFBP7] test result was
seen as just as informative and actionable as a positive
test, because low-risk patients may benefit from many
of the treatments best avoided in high-risk patients
(e.g., NSAIDs). There was strong consensus that
patients with a negative test were good candidates for
“fast-track” protocols and rapid de-escalation of moni-
toring (e.g., removal of arterial lines, indwelling urinary
catheters). Of note, five authors expressed that they had
originally doubted that the information provided by the
Table 1 [TIMP-2]•[IGFBP7] Protocol* Evaluation of existing clinical protocols: ranked order of actions and avoidances† by risk for AKI
Actions/avoidances Actions/avoidances Actions/avoidances
Low risk (≤ 0.3) Count High risk (> 0.3, ≤ 2.0) Count Highest risk (> 2) Count
Standard of care 13 No NSAIDs/ACE inhibitors/ARBs 20 Avoid aminoglycosides 6
Remove Foley 11 Keep/insert Foley 19 Renal ultrasound 5
Daily SCr 10 Hourly UO 19 Monitor SVV/Cardiac Index/SVO2 Q8–12 5
No HD monitoring 9 SCr Q8–12 19 Monitor fluid resuscitation 5
Recheck in 12 h if new insult 7 Avoid contrast 19 Maintenance fluids 5
Daily serum BUN 6 Consider/do renal consult 16 Send urine Na+, urea, creatinine 4
May use NSAIDs/ACE inhibitors 6 Recheck in 8–24 h 14 Check IVC compressibility with ultrasound 4
Diurese if signs of volume overload 6 Minimize/avoid nephrotoxins 13 Consider/use norepinephrine, epinephrine 4
SVO2 not monitored 5 Consider/use inotropes 11 Vasopressors 4
Mean hourly UO 4 Hold Lasix unless pulmonary
edema
11 Dobutamine/Milrinone 4
Consider transfer out of ICU 4 Adjust medication dosing 10 Avoid multiple pressors 4
Consider/do hemodynamic
monitoring
9 Sensible fluids 4
Adjust narcotics doses 9 Avoid and resolve hypervolemia (> 10%
fluid gain)
4
Consider colloids-only
approach
9 Maintain SBP > 90 3
Keep MAP > 65–80 8 Keep MAP ± 10% baseline 3
Serum BUN Q12 7 Consider higher transfusion trigger 3
Monitor SVO2 if history of
abnormal liver function
7 PA catheter 3
IVF expansion 7 Avoid piperacillin-tazobactam 3
May use balanced fluid if
CVP < 8 and hypovolemic
7 Low threshold for inotropes if Cardiac Index
< 2, ScvO2 < 70, and/or LA increasing despite
adequate MAP and volume expansion
3
Pharmacy consult 7 Goal SVV < 14 2
Urine Na, Cr, Eos ×1 6 Diuretics and fluids to be utilized only after
determining fluid status and need with FloTrac,
ultrasound, etc.
2
Goal CI > 2.0–2.2 6 Assess fluid responsiveness 2
Avoid vancomycin 6
*25 [TIMP-2]•[IGFBP7] protocols evaluated. †Actions/avoidances included in ≥ 2 protocols. ACE angiotensin-converting enzyme, AKI acute kidney injury, ARB
angiotensin-receptor blocker, BUN blood urea nitrogen, Cr creatinine, CVP central venous pressure, Eos eosinophils, HD hemodialysis, ICU intensive care unit, IVC
inferior vena cava, IVF intravenous fluid, MAP mean arterial pressure, Na sodium, NSAID nonsteroidal anti-inflammatory drug, PA pulmonary artery, SBP systolic
blood pressure, SCr serum creatinine, SVO2 venous oxygen saturation, UO urinary output, SVV stroke volume variation
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test would change clinical practice. Only after using the
test in several patients were they convinced.
Discussion
Clinical experts from the Europe and North America had
very similar experiences with the clinical use of the test.
Types of patients being tested and the types of actions
based on the test result were similar. More variation was
seen in terms of when to test. Some areas emphasized by
the participants warrant further discussion.
Which patients to test
All postoperative cardiac surgery patients
The Society of Thoracic Surgeons’Adult Cardiac Surgery
Database contains more than 6.5 million cardiac surgery
procedure records and currently has approximately 3800
participating physicians [9]. After cardiovascular surgery,
between 5 and 10% of patients develop kidney failure,
defined by a threefold increase in serum creatinine from
baseline or increase to a creatinine > 4 mg/dL (which
would be equivalent to KDIGO criteria stage 3 AKI by
creatinine [1]). Rates of AKI by full KDIGO criteria are
much higher, approaching 2 in 3 patients [10]. Specific
considerations for cardiac surgery patients include the
common practice of reducing circulating fluid volume
on cardiopulmonary bypass (hemoconcentration) often
resulting in postoperative oliguria. Current medical
literature has demonstrated that post-cardiac surgery
patients, identified as high risk by biomarker testing, and
randomized to a KDIGO treatment had up to a 34%
reduction in stage 2/3 AKI compared with those patients
randomized to standard of care [7]. Similar results were
reported for non-cardiac major surgery. [11]
Patients with shock or hemodynamic instability regardless
of the cause
Patients with shock, including hypovolemic, distributive/
septic, and cardiogenic, as well as patients with acute
decompensated heart failure, are at high risk for AKI.
Patients with sepsis
Sepsis is the most common cause of AKI in the ICU [12].
Patients with sepsis, particularly those with septic shock
also have more severe AKI—in a recent study, 44% of sep-
tic shock patients developed stage 2–3 AKI [13].
Unplanned admission to the ICU
Patients admitted to the ICU from the ward or emergency
department are often at high-risk for AKI, especially if they
are hemodynamically unstable or septic. The initial studies
validating [TIMP-2]•[IGFBP7] enrolled patients with car-
diovascular or respiratory failure going to the ICU [2]. For
practical purposes, this includes most unplanned admis-
sions and some planned postoperative admissions (e.g.,
cardiac surgery). Patients assessed for possible ICU admis-
sion by a rapid response team are also at high risk, and
[TIMP-2]•[IGFBP7] testing is currently being used by
some institutions to help evaluate and triage these patients.
Fig. 2 Developing proposed care pathway. A schematic representation of the steps involved before, during, and after the expert panel meetings
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When to test
For cardiac surgery patients, most measured [TIMP-
2]•[IGFBP7] within 4 h post-surgery. Performing the test
at a few different postoperative timepoints is helpful to
identify the most appropriate testing time for a particular
program given inherent differences in care across institu-
tions. Studies have reported a variety of results in this re-
gard. In several studies [14–16], [TIMP-2]•[IGFBP7]
detected elevations at 4 h; in another study, elevations
were not detected until the day after surgery [17]. A recent
study [18], with the most granular time-course published
to date, shows bimodal elevations of [TIMP-2]•[IGFBP7]
with the first peak occurring intraoperatively and the sec-
ond 6 h after ICU admission in patients who developed
stages 2/3 AKI. The authors postulate that the first peak
indicates kidney stress caused during the surgery, while
the second peak may indicate kidney stress caused during
early postoperative care. Measurement at both times re-
sulted in the best predictive ability, as would be expected
for two independent episodes of stress.
For patients in shock, [TIMP-2]•[IGFBP7] testing is
ordered as early as possible during patient evaluation.
Interestingly, there is emerging evidence in septic shock
that the post-resuscitation test results may be most pre-
dictive [19]. However, it also has been noted that when
test results improve (levels decrease) with resuscitation,
outcomes are better. There is therefore the hypothesis
that [TIMP-2]•[IGFBP7] testing might ultimately be
proven useful as a tool to monitor resuscitation efficacy.
Establishing clinical utility for this indication will require
studies that compare a biomarker-guided approach to a
standard approach. Such studies are currently lacking.
What actions to take and how to integrate the
technology into practice
Management of potential nephrotoxic medications was
the top priority in patients with positive test results. The
clinical panel participants agreed that all nonessential
nephrotoxic medications should be avoided. The combin-
ation of vancomycin and piperacillin-tazobactam, in
particular, has been noted to significantly increase risk for
AKI [20]. If vancomycin (or an aminoglycoside) is used, it
should be dosed strictly by levels, and its duration of use
should be as limited as possible. If a pharmacist is not
already part of the critical care team, consultation may be
appropriate. Likewise, NSAIDs and ACE inhibitors/ARBs
should be avoided in the early postoperative period.
A second category of high-priority actions involved
fluid management. Participants noted that patients with
a positive test result are at risk for fluid overload but
also might be volume depleted. There was strong con-
sensus therefore that a “goal-directed” approach to fluid/
diuretic management was essential. Two examples of
such an approach were published, one in 2017 in cardiac
surgery patients [7] and one in 2018 in non-cardiac sur-
gery patients [11]. In the first study, biomarker-positive
patients were randomized to receive a care bundle that
included a hemodynamic management algorithm based
on mean arterial pressure and stroke volume variation.
AKI was significantly reduced with the intervention
compared to controls (55.1 vs. 71.7%; ARR 16.6% (95%
CI 5.5–27.9%); p = 0.004). Rates of moderate to severe
AKI were also significantly reduced by the intervention
compared to controls (41/138 (29.7%) vs 62/138 (44.9%);
p = 0.009; OR, 0.518 (95% CI, 0.316–0.851); ARR, 15.2%
(95% CI, 4.0–26.5%)). The intervention resulted in sig-
nificantly improved hemodynamics (p < 0.05) as well as
less hyperglycemia (p < 0.001) and use of ACEi/ARBs
(p < 0.001) compared to controls. The total administered
volume was not different between the two groups, but
the distribution of fluid was different, with patients in
the intervention group receiving significantly less
volume during the last 3 h of the intervention period
(p = 0.024). However, there were no differences in rates
Table 2 Proposed target patient populations for [TIMP-
2]•[IGFBP7] testing
Tier 1
• Postoperative cardiovascular surgery
• Shock/Hemodynamically unstable
• Sepsis
• Postoperative major non-cardiovascular surgery
• Cardiac arrest, extracorporeal membrane oxygenation
• Oliguria after acute resuscitation
Tier 2
• Severe trauma (Injury Severity Score > 15)
• Acute illness/decompensation
• Elevated serum creatinine and no baseline
• Decompensated heart failure
• Acute respiratory distress syndrome/hypoxic respiratory failure
• Burn patients with total body surface area > 30%
• Anyone being seen by a rapid response team
• Solid organ (liver, heart, lung, kidney) transplants
• Receiving any nephrotoxic medications
• Any unplanned intensive care unit admission
• Suspected (impending) stage 2/3 acute kidney injury
• Volume depleted
• End-stage liver disease with early acute kidney injury
(± hepatorenal syndrome)
• Post-urologic procedure (e.g., partial / radical nephrectomy
or cystectomy)
Populations are listed in order of priority. Priorities assigned to the top three
populations were highest among all participants (scores > 35 out of a possible
48). The second tier was also highly ranked (> 20). The remaining populations
received lower priority rankings (10–20)
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of renal replacement therapy between intervention and
control either within 72 h (7.2% vs. 5.1%, p = 0.45), dur-
ing hospitalization (10.1% vs. 6.5%, p = 0.28), or at 30
days (3.1% vs. 2.3%. p = 0.72). Neither were there differ-
ences in mortality or persistent renal dysfunction at 30,
60, or 90 days.
In the second study [11], a similar care bundle including
early optimization of fluid status and maintenance of per-
fusion pressure, was applied to non-cardiac major surgery
patients after testing positive for the biomarker. Overall
AKI rates were not statistically different between groups
(19/60 (31.7%) in the intervention group vs. 29/61 (47.5%)
in the standard care group, p = 0.076). However, rates of
moderate and severe AKI, a secondary endpoint, were
reduced with the intervention (4/60 (6.7%) vs. 12/61
(19.7%), p = 0.04), as were lengths of ICU stay (median dif-
ference 1 day, p = 0.035) and hospital stay (median differ-
ence 5 days, p = 0.04). There were no significant
differences regarding renal replacement therapy, in-
hospital mortality, or major kidney events at hospital
Fig. 3 Protocol for [TIMP-2]•[IGFBP7] testing. ACEs, angiotensin-converting enzymes; AKI, acute kidney injury; ARBs, angiotensin-receptor blockers;
ICU, intensive care unit; NSAIDS, nonsteroidal anti-inflammatory drugs; UO, urinary output
Table 3 Consensus statements for potential actions after positive and negative [TIMP-2]•[IGFBP7] testing
Positive test (> 0.3) Negative test (≤ 0.3)
• Discontinue all nonessential nephrotoxins (e.g., NSAIDs)
• Avoid vancomycin or dose adjust
• Goal-directed fluid/diuretic management*
• Standard of care or fast-track
• Repeat [TIMP-2]•[IGFBP7] test if additional exposures occur
• Consider diuretics to maintain fluid balance
• Discontinue all ACE inhibitors and/or ARBs
• Maintain close UO monitoring
• Review meds with clinical pharmacist
• Retain invasive hemodynamic monitoring
• Avoid saline
• Consult nephrology
• Repeat [TIMP-2]•[IGFBP7] test in 12–24 h
• Consult intensive care
*Includes bedside ultrasound, and functional hemodynamic monitoring
Actions are listed in order of priority. High priority (> 30 out of a possible 48) was assigned to the top 5 actions. Actions that received a score < 12 (equivalent to
low priority by all participants and more than 25% of participants not supporting at all) were removed from the list
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discharge. Interestingly, 48-h cumulative balance was not
statistically different (2567ml (1617–3706) vs. 3207ml
(2015–4486), p = 0.085) but favored lower volumes in the
intervention group. This last finding brings to attention
the fact that “optimization” of fluid status for AKI patients
does not mean “give fluid” and frequently results in less
fluid.
As with any new technology, there are potential barriers
to adoption. The value proposition for new technology in-
volves both potential benefits as well as costs. Although a
cost-effectiveness analysis for the test is beyond the scope
of this report, it is notable that AKI is extremely expen-
sive—estimates put the cost at more than 19,000 USD
[21] to as much as 39,000 USD per case [22]. By compari-
son, the test itself retails for approximately 100 USD per
determination. However, the test will not be useful in all
patients, and protocols should define appropriate lines of
communication to ensure that the [TIMP-2]•[IGFBP7]
test is ordered for the appropriate patients. Given that
[TIMP-2]•[IGFBP7] provides an early warning of kidney
stress, the test results are most valuable when reported
promptly. Therefore, the [TIMP-2]•[IGFBP7] should be
ordered as a “stat” (i.e., as soon as possible) test so that re-
sults are available as quickly as possible. Most participants
reported a 1-h turn around by their clinical lab. By insti-
tuting an AKI biomarker protocol, hospitals have the op-
portunity to develop and test metrics that can enhance
quality improvement initiatives.
As part of [TIMP-2]•[IGFBP7] test protocol integration,
the inclusion of information technology and the electronic
health record (EHR)/electronic medical record (EMR) sys-
tem is imperative to ensure that test reporting is online,
and the test is used consistently. The test may become a
part of cardiopulmonary bypass protocols and can be
added as an EHR order. It is helpful to provide sample pro-
tocols and data to demonstrate what is needed. If [TIMP-
2]•[IGFBP7] testing is effectively integrated into these
systems, it also may be beneficial to expand testing into
other hospital systems and networks. For example, [TIMP-
2]•[IGFBP7] testing could work well in other ICUs, for all
patients admitted with shock, the emergency department,
and/or trauma unit, as well as operating rooms.
Despite its brief history, dozens of studies have evaluated
the diagnostic value of [TIMP-2]•[IGFBP7] for AKI, in vari-
ous settings (e.g., cardiac surgery, ICU, emergency depart-
ment/trauma), different patient populations (e.g., KDIGO
criteria, elderly, high-risk surgeries), and measurement cri-
teria (e.g., thresholds, sampling times). Detailed discussion
of these studies is beyond the scope of this report, but sev-
eral systematic reviews are available [23–27]. Overall,
[TIMP-2]•[IGFBP7] is accurate in identifying patients at
risk for AKI. However, to our knowledge, only two studies,
thus far, have attempted to evaluate whether use of the test
alters the clinical course of AKI [7, 11]. Thus, future
research is warranted to better understand how treatment
protocols based on [TIMP-2]•[IGFBP7] results can
improve outcomes.
Conclusions
Clinical experts have developed very similar practice pat-
terns for use of the [TIMP-2]•[IGFBP7] test on both
sides of the Atlantic. Strong consensus was achieved for
whom to test, how to interpret a test result, and for the
actions to take based on test results. Importantly, many
actions listed in Table 1, though common in clinical
practice, are not supported by scientific evidence but ra-
ther reflect the clinical judgment of the authors. Less
consensus was present on when to test, but this also
reflected different patient populations. In general, testing
needs to occur early but only after a potential inciting
event has occurred. Patients undergoing major surgery
(cardiac or non-cardiac), those with hemodynamic
instability, or those with sepsis were believed to be the
top priority patient populations for the biomarker test.
Top actions for positive tests involve management of
nephrotoxic drugs as well as fluids. Patients testing
negative were considered to be excellent candidates for
“fast-track” protocols.
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NSAID: Nonsteroidal anti-inflammatory drug; SBP: Systolic blood pressure;
SCr: Serum creatinine; SVO2: Venous oxygen saturation; TIMP-2: Tissue
inhibitor of metalloproteinases-2; UO: Urinary output
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